Anonymous v Merck Sharp & Dohme: Cerazette ‘retrospective rebate’ allegation (AUTH/2599/4/13) – No breach

📅 2013 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2599/4/13
PartiesAnonymous (non-contactable) v Merck Sharp & Dohme Limited
ProductCerazette (oral contraceptive)
Main allegationRetrospective rebate scheme offered to clinics/hospitals over 12 months as an inducement to prescribe
Clauses consideredClause 2; Clause 18.1
Company positionNo retrospective rebate; only non-retrospective discounts via national purchasing authorities (hospital tenders) and pre-agreed clinic discounts; no personal benefit to HCPs/staff
Panel findingNo evidence the alleged retrospective rebate existed; complainant did not discharge burden of proof
OutcomeNo breach of Clauses 18.1 and 2
Complaint received30 April 2013
Case completed30 May 2013
Applicable Code year2012
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous, non-contactable complainant alleged Merck Sharp & Dohme (MSD) offered clinics/hospitals a retrospective rebate on Cerazette use over a 12‑month period to counter loss of share after generics launched.
  • The complainant alleged this was an inducement to prescribe, raising a prima facie concern under Clause 2.
  • The PMCPA asked MSD to also consider Clause 18.1 (terms of trade/inducements) in its response.
  • MSD denied any retrospective rebate scheme and described only non-retrospective discounts: (1) NHS hospital supply contracts agreed via national purchasing authorities through formal tendering/contracting; (2) discounted supply to some family planning clinics agreed prior to purchase.
  • The Panel noted the complainant could not be contacted and therefore had to decide the case on the evidence provided; the complainant carried the burden of proof on the balance of probabilities.
⚖️

Outcome

  • No breach of the Code was found.
  • No breach of Clause 18.1.
  • No breach of Clause 2.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training